Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily after initial success

Abstract

The reliability of response to treatment is an important component of erectile dysfunction (ED) treatment. This study examined the reliability of tadalafil once daily (that is, successful attempts/total attempts) following initial successful intercourse. Data pooled from two randomized, double-blind, placebo-controlled trials of men with ED who received tadalafil 2.5 mg (N=96), tadalafil 5 mg (N=206) or placebo (N=148) once daily were analyzed to determine the first-attempt success rate and subsequent reliability of response. The first-attempt success rate (Sexual Encounter Profile question 3 (SEP3)) was significantly higher among men taking tadalafil 2.5 mg (45.7%) and 5 mg (55.2%) compared to placebo (28.5%; P<0.05 and P<0.001, respectively). Furthermore, following initial success, men taking tadalafil 5 mg had a significantly greater proportion of successful intercourse (SEP3) on subsequent attempts (85.9%, P<0.001) compared to men taking placebo (70.2%). Overall, men with ED taking tadalafil once daily experienced a high rate of reliability of efficacy.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83–90.

    Article  Google Scholar 

  2. Ayta IA, McKinlay JB, Krane RJ . The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50–56.

    Article  CAS  Google Scholar 

  3. McKinlay JB . The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000; 12 (Suppl 4): S6–S11.

    Article  Google Scholar 

  4. Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson KE, Althof S et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004; 1: 6–23.

    Article  Google Scholar 

  5. Schulman CC, Shen W, Stothard DR, Schmitt H . Integrated analysis examining first-dose success, success by dose, and maintenance of success among men taking tadalafil for erectile dysfunction. Urology 2004; 64: 783–788.

    Article  Google Scholar 

  6. Montorsi F, Hellstrom WJ, Valiquette L, Bastuba M, Collins O, Taylor T et al. Vardenafil provides reliable efficacy over time in men with erectile dysfunction. Urology 2004; 64: 1187–1195.

    Article  Google Scholar 

  7. Fugl-Meyer AR, Lodnert G, Bränholm IB, Fugl-Meyer KS . On life satisfaction in male erectile dysfunction. Int J Impot Res 1997; 9: 141–148.

    Article  CAS  Google Scholar 

  8. Althof SE . Quality of life and erectile dysfunction. Urology 2002; 59: 803–810.

    Article  Google Scholar 

  9. Porst H, Giuliano F, Glina S, Ralph D, Casabé AR, Elion-Mboussa A . Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006; 50: 351–359.

    Article  CAS  Google Scholar 

  10. Rajfer J, Aliotta PJ, Steidle CP, Fitch III WP, Zhao Y, Yu A . Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res 2007; 19: 95–103.

    Article  CAS  Google Scholar 

  11. Hatzichristou D, Gambla M, Rubio-Aurioles E, Buvat J, Brock GB, Spera G et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med 2008; 25: 138–146.

    Article  CAS  Google Scholar 

  12. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A . The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–830.

    Article  CAS  Google Scholar 

  13. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH . Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 346–351.

    Article  CAS  Google Scholar 

  14. Rosen RC, Cappelleri JC, Gendrano III N . The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res 2002; 14: 226–244.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by Lilly USA, LLC, including assistance with the article preparation provided by Danette Hann, PhD, i3 Statprobe.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R Shabsigh.

Additional information

Disclaimer: Tadalafil is currently only approved for the treatment of erectile dysfunction.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shabsigh, R., Donatucci, C., Costabile, R. et al. Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily after initial success. Int J Impot Res 22, 1–8 (2010). https://doi.org/10.1038/ijir.2009.29

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2009.29

Keywords

This article is cited by

Search

Quick links